Stoke Therapeutics Inc STOK:NASDAQ

Last Price$14.89NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$10.17 (1)
Ask (Size)$27.00 (4)
Day Low / HighN/A - N/A
Volume375.0 K

Acadia, Stoke to Develop RNA-Based Treatments for Genetic Neurological Disorders

10:52AM ET 1/10/2022 MT Newswires
Acadia Pharmaceuticals (ACAD) and Stoke Pharmaceuticals (STOK) said Monday they have formed a partnership to discover, develop and commercialize novel RNA-based treatment for severe and rare genetic neurodevelopmental diseases.

The collaboration covers Stoke's SYNGAP1 preclinical program, as well as preclinical programs for Rett syndrome and an undisclosed neurodevelopmental target.

Under the terms of the collaboration, Stoke will receive $60 million in upfront payment, up to $907 million in potential milestone payments, as well as royalties on future sales from Acadia.

Acadia shares were 2.8% lower while Stoke shares were down 3.6% in morning trading.

Price: 21.97, Change: -0.62, Percent Change: -2.74